普拉克索治疗原发性不安腿综合征疗效观察

目的观察普拉克索治疗原发性不安腿综合征（RLS）的临床疗效及安全性。方法将66例原发性RLS患者随机分为普拉克索组与美多巴组，应用国际不安腿综合征评估量表（IRLS）和汉密尔顿抑郁量表（HAMD）分别于治疗前及治疗后6周进行病情评估，观察比较2组治疗前后各量表评分情况，并记录2组患者出现的药物不良反应。结果2组患者治疗后IRLS与HAMD评分较治疗前均明显下降（P〈0．05），相比美多巴组，普拉克索组治疗后IRLS评分差异无统计学意义（P〉0．05），但HAMD评分下降更为明显（P〈0．01），2组药物不良反应发生率差异无统计学意义（P〉0．05）。结论普拉克索能有效缓解原发性RLS症状，且药物不良反应较小，相比美多巴其抗抑郁的优势更为明显。

Clinical efficacy of pramipexole in the treatment of primary restless legs syndrome

Objective To observe the clinical efficacy and safety of pramipexol in treating patients with primary restless legs syndrome （RLS）. Methods Sixty-six patients with RLS were randomly divided in the pramipexol group and madopargroup, both groups were assessed and compared with international RLS study group rating scale （IRLS）and Hamiltondepression scale（HAMD）before treatment and 6 weeks after treatment. The record of the side-effect of pramipexol was made at the same time. Results The scores of IRLS and HAMD of the two groups were decreased distinetively after treatment（P~ 0.05）. Compared with madopar group, the score of HAMD after treatment in pramipexol group was significantly different（P 〈0.01）, but not in the score of IRLS（P〉0.05）. There was no significant difference in the incidence of side-effect between pramipexol and madopar（P〉0.05）. Conclusion Pramipexole is efficacious and safe in reducing the symptoms of RLS,and is better in anti-depression compared with madopar.